Deze aankondiging is gebaseerd op een persbericht van Lexicon Pharmaceuticals. De toekomstgerichte verklaringen van het bedrijf zijn onderhevig aan risico's en onzekerheden, en er is geen garantie dat ...

Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $0.71 which represents a slight increase of $0.06 or 9.23% from the prior close of $0.65. The stock opened at $0.66 and ...

One of those studies, a secondary analysis of data from the Phase 3 THE WOODLANDS, Texas (AP) — Lexicon Pharmaceuticals Inc. LXRX) on Tuesday reported a loss of $64.8 million in its third quarter.

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). | Acadia ...

Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development.

On Monday, Lexicon Pharmaceuticals (NASDAQ:LXRX) experienced a revision in its stock forecast. H.C. Wainwright, a financial services firm, adjusted the price target for Lexicon Pharmaceuticals to ...

Benieuwd naar onze analyses en kooptips? Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer ...